143 related articles for article (PubMed ID: 36378065)
1. Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease.
Tamai H; Okamura J
Hepatol Res; 2023 Mar; 53(3):258-266. PubMed ID: 36378065
[TBL] [Abstract][Full Text] [Related]
2. Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia.
Nishida M; Horio T; Fukuda Y; Hayakawa Y; Tateishi Y; Akai M; Emoto M; Hasegawa T; Imanishi M
Int J Clin Pharmacol Ther; 2023 Oct; 61(10):437-444. PubMed ID: 37548458
[TBL] [Abstract][Full Text] [Related]
3. Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis.
Dohmen K; Onohara SY; Harada S
Korean J Gastroenterol; 2021 Oct; 78(4):227-234. PubMed ID: 34697277
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.
Nakamura A; Kagaya Y; Saito H; Kanazawa M; Sato K; Miura M; Kondo M; Endo H
J Atheroscler Thromb; 2023 May; 30(5):443-454. PubMed ID: 35768226
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease.
Yamada-Shimizu M; Tamaki N; Kurosaki M; Uchihara N; Suzuki K; Tanaka Y; Miyamoto H; Ishido S; Nobusawa T; Matsumoto H; Keitoku T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
Intern Med; 2024 May; 63(9):1185-1190. PubMed ID: 37779070
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis.
Joshita S; Umemura T; Yamashita Y; Sugiura A; Yamazaki T; Fujimori N; Matsumoto A; Tanaka E
Hepatol Res; 2019 Oct; 49(10):1236-1243. PubMed ID: 31077509
[TBL] [Abstract][Full Text] [Related]
7. Safety of fibrates in cholestatic liver diseases.
Carrion AF; Lindor KD; Levy C
Liver Int; 2021 Jun; 41(6):1335-1343. PubMed ID: 33751787
[TBL] [Abstract][Full Text] [Related]
8. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
[TBL] [Abstract][Full Text] [Related]
9. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.
Horinouchi Y; Murashima Y; Yamada Y; Yoshioka S; Fukushima K; Kure T; Sasaki N; Imanishi M; Fujino H; Tsuchiya K; Shinomiya K; Ikeda Y
Life Sci; 2023 May; 321():121590. PubMed ID: 36940907
[TBL] [Abstract][Full Text] [Related]
10. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases.
Yamashita S; Masuda D; Matsuzawa Y
J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344
[TBL] [Abstract][Full Text] [Related]
11. A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients.
Yanai H; Katsuyama H; Hakoshima M
Cardiol Res; 2021 Dec; 12(6):358-362. PubMed ID: 34970366
[TBL] [Abstract][Full Text] [Related]
12. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
Nakajima A; Eguchi Y; Yoneda M; Imajo K; Tamaki N; Suganami H; Nojima T; Tanigawa R; Iizuka M; Iida Y; Loomba R
Aliment Pharmacol Ther; 2021 Nov; 54(10):1263-1277. PubMed ID: 34528723
[TBL] [Abstract][Full Text] [Related]
13. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
Honda Y; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Takizawa T; Saito S; Nagashima Y; Nakajima A
Sci Rep; 2017 Feb; 7():42477. PubMed ID: 28195199
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S;
J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.
Iwasaki M; Suzuki H; Umezawa Y; Koshida T; Saito M; Fukuda H; Takahara H; Matsuzaki K; Suzuki Y
Medicine (Baltimore); 2023 Feb; 102(7):e32818. PubMed ID: 36800602
[TBL] [Abstract][Full Text] [Related]
16. Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study.
Yanai H; Katsuyama H; Hakoshima M
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203610
[TBL] [Abstract][Full Text] [Related]
17. Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia.
Tanaka A; Nakamura T; Sato E; Chihara A; Node K
CEN Case Rep; 2020 May; 9(2):141-146. PubMed ID: 31950425
[TBL] [Abstract][Full Text] [Related]
18. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
de Vries E; Bolier R; Goet J; Parés A; Verbeek J; de Vree M; Drenth J; van Erpecum K; van Nieuwkerk K; van der Heide F; Mostafavi N; Helder J; Ponsioen C; Oude Elferink R; van Buuren H; Beuers U;
Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
[TBL] [Abstract][Full Text] [Related]
19. Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.
Lemoinne S; Pares A; Reig A; Ben Belkacem K; Kemgang Fankem AD; Gaouar F; Poupon R; Housset C; Corpechot C; Chazouillères O
Clin Res Hepatol Gastroenterol; 2018 Dec; 42(6):521-528. PubMed ID: 30100231
[TBL] [Abstract][Full Text] [Related]
20. Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease.
Shinozaki S; Tahara T; Lefor AK; Ogura M
Clin Exp Hepatol; 2020 Sep; 6(3):270-274. PubMed ID: 33145434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
